Booz Allen Hamilton vs Genpact
BAH and G side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BAH and G compare
Booz Allen Hamilton is the larger company, worth 1.4 times as much as Genpact ($10.2B against $7.3B).
On earnings, Genpact is cheaper: it trades at 12.7× trailing earnings, against 13.3× for Booz Allen Hamilton.
Genpact grew revenue faster over the last twelve months (6.7% versus −6.2% for Booz Allen Hamilton).
Genpact keeps more of each dollar of sales as profit, with a net margin of 11.0% compared with 7.1% at Booz Allen Hamilton.
Both pay dividends: Booz Allen Hamilton yields 2.7% and Genpact 1.3%.
Genpact scores higher on the StockData Score (21 against 19 for Booz Allen Hamilton), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BAH | G |
|---|---|---|
| Size and price | ||
| Market cap | $10.2B | $7.3B |
| Share price | $86.22 | $43.61 |
| Change, 1 year | 1.6% | −4.2% |
| Change, 5 years | −1.3% | −14.1% |
| Beta (5Y) | 0.62 | 0.65 |
| Employees | 32K | 147K |
| StockData Score | ||
| Total score | 19 | 21 (better) |
| Valuation score | 5 | 5 |
| Growth score | 1 | 3 (better) |
| Performance score | 6 | 6 |
| Health score | 3 | 4 (better) |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 13.3× | 12.7× (better) |
| P/S | 0.9× (better) | 1.4× |
| P/B | 8.2× | 2.7× (better) |
| EV/EBITDA | 12.0× | 10.0× (better) |
| P/FCF | 10.4× (better) | 20.6× |
| PEG | 0.27 (better) | 0.69 |
| FCF yield | 9.6% (better) | 4.9% |
| Fair value | $125.06 | $57.11 |
| Margin of safety | 31.1% (better) | 23.6% |
| Growth | ||
| Revenue growth (TTM) | −6.2% | 6.7% (better) |
| Revenue growth, 5Y average | 7.4% (better) | 6.5% |
| Net income growth (TTM) | −5.1% | 6.7% (better) |
| EPS growth (TTM) | −1.5% | 10.6% (better) |
| EPS growth, 5Y average | 9.6% | 14.8% (better) |
| Profitability | ||
| Gross margin | 52.5% (better) | 36.9% |
| Operating margin | 9.3% | 14.9% (better) |
| Net margin | 7.1% | 11.0% (better) |
| FCF margin | 9.0% (better) | 6.7% |
| Return on equity | 70.0% (better) | 22.4% |
| Return on invested capital | 19.5% (better) | 19.1% |
| Financial health | ||
| Debt / equity | 3.55 | 0.43 (better) |
| Net debt / EBITDA | 3.41 | 0.85 (better) |
| Current ratio | 1.43 | 1.95 (better) |
| Altman Z-score | 3.37 | 3.55 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.7% (better) | 1.3% |
| Payout ratio | 36.1% | 21.0% |
| Years of dividend growth | 8 (better) | 6 |
| Dividend growth, 5Y average | 11.5% | 11.8% (better) |
| Buyback yield | 3.3% | – |
| Shareholder yield | 6.0% (better) | 1.3% |
| Ownership | ||
| Held by institutions | 97.7% | 107% |
| Held by insiders | 1.3% | 35.7% |
| Insider net buying, 12 months | −$363K (better) | −$4.0M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 5.5% | 9.9% |
Go deeper
- BAH stock overview
- BAH income statement
- BAH valuation and score
- G stock overview
- G income statement
- G valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.